Houghton, P. J., Maris, J. M., Friedman, H. S., Keir, S. T., Lock, R. B., Gorlick, R., … Smith, M. A. (2006). 313 POSTER Pediatric preclinical testing program (PPTP) evaluation of the KSP inhibitor Ispinesib (SB-715992). European Journal of Cancer Supplements, 4(12), 98–98. https://doi.org/10.1016/s1359-6349(06)70318-4

Houghton, P. J., J. M. Maris, H. S. Friedman, S. T. Keir, R. B. Lock, R. Gorlick, E. A. Kolb, C. P. Reynolds, C. Morton, and M. A. Smith. “313 POSTER Pediatric preclinical testing program (PPTP) evaluation of the KSP inhibitor Ispinesib (SB-715992).” European Journal of Cancer Supplements 4, no. 12 (November 2006): 98–98. https://doi.org/10.1016/s1359-6349(06)70318-4.

Houghton PJ, Maris JM, Friedman HS, Keir ST, Lock RB, Gorlick R, et al. 313 POSTER Pediatric preclinical testing program (PPTP) evaluation of the KSP inhibitor Ispinesib (SB-715992). European Journal of Cancer Supplements. 2006 Nov;4(12):98–98.

Houghton, P. J., et al. “313 POSTER Pediatric preclinical testing program (PPTP) evaluation of the KSP inhibitor Ispinesib (SB-715992).” European Journal of Cancer Supplements, vol. 4, no. 12, Elsevier BV, Nov. 2006, pp. 98–98. Crossref, doi:10.1016/s1359-6349(06)70318-4.

Houghton PJ, Maris JM, Friedman HS, Keir ST, Lock RB, Gorlick R, Kolb EA, Reynolds CP, Morton C, Smith MA. 313 POSTER Pediatric preclinical testing program (PPTP) evaluation of the KSP inhibitor Ispinesib (SB-715992). European Journal of Cancer Supplements. Elsevier BV; 2006 Nov;4(12):98–98.